These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30358019)

  • 61. Conversion from twice-daily to once-daily tacrolimus formulation in pediatric liver transplant recipients - a long-term prospective study.
    Quintero J; Juampérez J; Ortega J; Molino JA; Castells L; Bilbao I; Rodrigo C; Charco R
    Transpl Int; 2018 Jan; 31(1):38-44. PubMed ID: 28833714
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.
    Grinyó JM; Petruzzelli S
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1567-79. PubMed ID: 25407098
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation.
    Musuamba FT; Guy-Viterbo V; Reding R; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2014 Feb; 36(1):54-61. PubMed ID: 24081207
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
    Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
    Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
    Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients.
    Bloom RD; Trofe-Clark J; Wiland A; Alloway RR
    Clin Transplant; 2013; 27(6):E685-93. PubMed ID: 24118450
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2020 Dec; 52(10):3238-3245. PubMed ID: 33218668
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus.
    Lauzurica R; Morales JM; van Hooff J;
    Transpl Int; 2012 Jan; 25(1):48-55. PubMed ID: 21992068
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
    Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE
    Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and Efficacy of Reduced Prolonged-release Tacrolimus Exposure in De Novo Kidney Transplantation: A Randomized, Open-label, Pilot Study in Asia-OPTIMIZE Study.
    Kim YH; Chiang YJ; Kim SJ; Kim MS; Park SB; Wu ST; Horita K; Nakashima Y; Jiang H; Han DJ
    Transplant Direct; 2019 Apr; 5(4):e340. PubMed ID: 30993185
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations.
    Fontova P; van Merendonk LN; Vidal-Alabró A; Rigo-Bonnin R; Cerezo G; van Oevelen S; Bestard O; Melilli E; Montero N; Coloma A; Manonelles A; Torras J; Cruzado JM; Grinyó JM; Colom H; Lloberas N
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242723
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early Use of Tacrolimus Extended-Release in a Pediatric Kidney Transplant Recipient.
    Szempruch KR; Westreich KD; Toledo AH
    Exp Clin Transplant; 2021 Aug; 19(8):865-867. PubMed ID: 29206086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug-drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults.
    Zhao X; Lu X; Zuo M; Wang N; Zhang Y; Chen J; Zhu L; Liu W
    Xenobiotica; 2021 Aug; 51(8):877-884. PubMed ID: 34151692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early Outcomes From de Novo Weight-Based Dosing Compared With Conservative Dosing of Tacrolimus in Kidney Transplant Recipients: A Multisite Perspective.
    Maldonado AQ; Summers B; Szempruch KR; Hall J; Harris MT
    Ann Pharmacother; 2017 Jun; 51(6):518-519. PubMed ID: 28478720
    [No Abstract]   [Full Text] [Related]  

  • 79. Clinical pharmacokinetics of tacrolimus.
    Venkataramanan R; Swaminathan A; Prasad T; Jain A; Zuckerman S; Warty V; McMichael J; Lever J; Burckart G; Starzl T
    Clin Pharmacokinet; 1995 Dec; 29(6):404-30. PubMed ID: 8787947
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
    Rubik J; Debray D; Kelly D; Iserin F; Webb NJA; Czubkowski P; Vondrak K; Sellier-Leclerc AL; Rivet C; Riva S; Tönshoff B; D'Antiga L; Marks SD; Reding R; Kazeem G; Undre N
    Transpl Int; 2019 Nov; 32(11):1182-1193. PubMed ID: 31325368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.